MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- CADILA HEALTHCARE - ASTRAZENECA PHARMA
CADILA HEALTHCARE vs ASTRAZENECA PHARMA - Comparison Results
CADILA HEALTHCARE 
Change
Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
ASTRAZENECA PHARMA
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Current Valuations
| CADILA HEALTHCARE | ASTRAZENECA PHARMA | CADILA HEALTHCARE/ ASTRAZENECA PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 13.7 | 91.9 | 14.9% | View Chart |
| P/BV | x | 2.9 | 20.3 | 14.2% | View Chart |
| Dividend Yield | % | 1.4 | 0.0 | - |
Financials
 CADILA HEALTHCARE  ASTRAZENECA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CADILA HEALTHCARE Mar-18 |
ASTRAZENECA PHARMA Mar-18 |
CADILA HEALTHCARE/ ASTRAZENECA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 558 | 1,278 | 43.7% | |
| Low | Rs | 362 | 883 | 41.0% | |
| Sales per share (Unadj.) | Rs | 116.3 | 228.4 | 50.9% | |
| Earnings per share (Unadj.) | Rs | 17.9 | 10.4 | 172.4% | |
| Cash flow per share (Unadj.) | Rs | 23.1 | 16.3 | 142.3% | |
| Dividends per share (Unadj.) | Rs | 3.50 | 0 | - | |
| Dividend yield (eoy) | % | 0.8 | 0 | - | |
| Book value per share (Unadj.) | Rs | 85.4 | 98.8 | 86.5% | |
| Shares outstanding (eoy) | m | 1,023.74 | 25.00 | 4,095.0% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.0 | 4.7 | 83.6% | |
| Avg P/E ratio | x | 25.7 | 104.2 | 24.7% | |
| P/CF ratio (eoy) | x | 19.9 | 66.4 | 29.9% | |
| Price / Book Value ratio | x | 5.4 | 10.9 | 49.2% | |
| Dividend payout | % | 19.6 | 0 | - | |
| Avg Mkt Cap | Rs m | 470,664 | 27,008 | 1,742.7% | |
| No. of employees | `000 | 11.8 | 1.4 | 871.6% | |
| Total wages/salary | Rs m | 18,545 | 1,535 | 1,207.9% | |
| Avg. sales/employee | Rs Th | 10,072.7 | 4,210.9 | 239.2% | |
| Avg. wages/employee | Rs Th | 1,569.1 | 1,132.2 | 138.6% | |
| Avg. net profit/employee | Rs Th | 1,547.7 | 191.1 | 810.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 119,049 | 5,710 | 2,084.9% | |
| Other income | Rs m | 1,132 | 123 | 924.1% | |
| Total revenues | Rs m | 120,181 | 5,833 | 2,060.5% | |
| Gross profit | Rs m | 28,475 | 463 | 6,151.4% | |
| Depreciation | Rs m | 5,388 | 147 | 3,655.4% | |
| Interest | Rs m | 911 | 0 | - | |
| Profit before tax | Rs m | 23,308 | 438 | 5,321.5% | |
| Minority Interest | Rs m | 628 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 5,644 | 179 | 3,154.8% | |
| Profit after tax | Rs m | 18,292 | 259 | 7,059.8% | |
| Gross profit margin | % | 23.9 | 8.1 | 295.0% | |
| Effective tax rate | % | 24.2 | 40.8 | 59.3% | |
| Net profit margin | % | 15.4 | 4.5 | 338.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 82,005 | 3,209 | 2,555.3% | |
| Current liabilities | Rs m | 60,720 | 2,070 | 2,934.0% | |
| Net working cap to sales | % | 17.9 | 20.0 | 89.6% | |
| Current ratio | x | 1.4 | 1.6 | 87.1% | |
| Inventory Days | Days | 73 | 72 | 101.1% | |
| Debtors Days | Days | 98 | 35 | 281.5% | |
| Net fixed assets | Rs m | 83,703 | 790 | 10,591.3% | |
| Share capital | Rs m | 1,024 | 50 | 2,048.0% | |
| "Free" reserves | Rs m | 86,421 | 2,419 | 3,572.1% | |
| Net worth | Rs m | 87,445 | 2,469 | 3,541.3% | |
| Long term debt | Rs m | 25,551 | 0 | - | |
| Total assets | Rs m | 180,653 | 4,605 | 3,922.6% | |
| Interest coverage | x | 26.6 | NM | - | |
| Debt to equity ratio | x | 0.3 | 0 | - | |
| Sales to assets ratio | x | 0.7 | 1.2 | 53.2% | |
| Return on assets | % | 10.6 | 5.6 | 188.9% | |
| Return on equity | % | 20.9 | 10.5 | 199.4% | |
| Return on capital | % | 22.0 | 17.7 | 124.0% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 42,683 | 300 | 14,249.0% | |
| Fx outflow | Rs m | 11,242 | 2,015 | 557.9% | |
| Net fx | Rs m | 31,441 | -1,715 | -1,832.9% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 9,193 | 88 | 10,458.5% | |
| From Investments | Rs m | -9,737 | -94 | 10,402.8% | |
| From Financial Activity | Rs m | 515 | NA | - | |
| Net Cashflow | Rs m | -29 | -6 | 508.8% | |
Share Holding
| Indian Promoters | % | 74.8 | 0.0 | - | |
| Foreign collaborators | % | 0.0 | 75.0 | - | |
| Indian inst/Mut Fund | % | 8.3 | 0.3 | 2,766.7% | |
| FIIs | % | 5.9 | 15.7 | 37.6% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 11.0 | 9.1 | 120.9% | |
| Shareholders | 44,069 | 12,856 | 342.8% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CADILA HEALTHCARE With: VENUS REMEDIES SHASUN PHARMA PFIZER TTK HEALTHCARE ORCHID PHARMA LTD
Compare CADILA HEALTHCARE With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 234 Points Higher; Healthcare and Realty Stocks Rally(Closing)
After opening the day on a flat note, Indian share markets witnessed buying interest during closing hours and ended higher.
Related Views on News
CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Mar 29, 2019 | Updated on Mar 29, 2019Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.
ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsMost Popular
I Believe this is the Best Stock to Buy Today(Profit Hunter)
Jul 3, 2019The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.
These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)
Jul 9, 2019As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.
2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)
Jul 12, 2019Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.
After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)
Jul 8, 2019A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...
Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)
Jul 5, 2019Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?
More|
| |
CADILA HEALTHCARE SHARE PRICE
Jul 16, 2019 (Close)
TRACK CADILA HEALTHCARE
- Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CADILA HEALTHCARE
CADILA HEALTHCARE - DIVIS LABORATORIES COMPARISON
COMPARE CADILA HEALTHCARE WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.